Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum

Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare disease, and many cases are either benign neoplasms or low-graded malignancies; however, a few cases show rapid progressive clinical courses. No effective therapy has yet been established for WDPMP, and the molecular basi...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics 2012-11, Vol.205 (11), p.594-598
Main Authors: Nemoto, Hiroshi, Tate, Genshu, Kishimoto, Koji, Saito, Mitsuo, Shirahata, Atsushi, Umemoto, Takehiro, Matsubara, Taketo, Goto, Tetsuhiro, Mizukami, Hiroki, Kigawa, Gaku, Mitsuya, Toshiyuki, Hibi, Kenji
Format: Article
Language:English
Subjects:
Aged
Benign
DNA Mutational Analysis
E2F1
E2F1 Transcription Factor - genetics
Fatal Outcome
Female
Genes, Neurofibromatosis 2
Hematology, Oncology and Palliative Medicine
heterozygous loss
Histocytochemistry
Humans
Loss of Heterozygosity
Medical Education
mesothelioma
Mesothelioma - genetics
Mesothelioma - pathology
Mesothelioma - surgery
NF2
Peritoneal Neoplasms - genetics
Peritoneal Neoplasms - pathology
Polymorphism, Single Nucleotide
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Well-differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare disease, and many cases are either benign neoplasms or low-graded malignancies; however, a few cases show rapid progressive clinical courses. No effective therapy has yet been established for WDPMP, and the molecular basis of WDPMP tumorigenesis has never been reported. This study shows the malignant transformation of WDPMP in a Japanese female patient, who was alive for 54 months after the initial diagnosis by a laparoscopic biopsy. A molecular analysis of single nucleotide polymorphisms (SNPs), which were located in the neurofibromatosis type 2 ( NF2 ) gene, a tumor suppressor gene assigned to chromosome 22q12.3, revealed the loss of heterozygosity (LOH) of the NF2 gene. Furthermore, SNP analyses determined that LOH was observed in the IL17RA (22q11.1), CHECK2 (22q12.1), and SHANK3 (22q13.3) genes, thus suggesting that NF2 loss occurred through 22q deletions or monosomy 22. The LOH of the NF2 gene was observed in an early stage of WDPMP, thus indicating that LOH of the NF2 gene is an early molecular alteration, and NF2 loss is a molecular mechanism associated not only with malignant pleural mesothelioma, but also with WDPMP.
ISSN:2210-7762
2210-7770
DOI:10.1016/j.cancergen.2012.08.005